AU2003259391A1 - Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia - Google Patents

Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia

Info

Publication number
AU2003259391A1
AU2003259391A1 AU2003259391A AU2003259391A AU2003259391A1 AU 2003259391 A1 AU2003259391 A1 AU 2003259391A1 AU 2003259391 A AU2003259391 A AU 2003259391A AU 2003259391 A AU2003259391 A AU 2003259391A AU 2003259391 A1 AU2003259391 A1 AU 2003259391A1
Authority
AU
Australia
Prior art keywords
piperazin
dione
metabolites
methoxyphenyl
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259391A
Inventor
Nitya Anand
Anita Chugh
Sanjay Jain
Gobind Singh Kapkoti
Anita Mehta
Jyoti Kumar Paliwal
Somesh Sharma
Neelima Sinha
Gyan Chand Yadav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2003259391A1 publication Critical patent/AU2003259391A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
AU2003259391A 2003-08-25 2003-08-25 Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia Abandoned AU2003259391A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/003509 WO2005018643A1 (en) 2003-08-25 2003-08-25 Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
AU2003259391A1 true AU2003259391A1 (en) 2005-03-10

Family

ID=34204110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259391A Abandoned AU2003259391A1 (en) 2003-08-25 2003-08-25 Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia

Country Status (2)

Country Link
AU (1) AU2003259391A1 (en)
WO (1) WO2005018643A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1758583A2 (en) * 2004-05-31 2007-03-07 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as adrenergic receptor antagonists
WO2007029078A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Succinimide and glutarimide derivatives as adrenergic receptor antagonists
WO2007039809A1 (en) * 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited Metabolites of 2- {3-[4-(5-fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl} -5,6-dihydroxy-hexahydro-isoindole-1,3-dione
CN104030933A (en) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 Method for synthesizing beta-isoalkanol amino valeric acid cyclohexylamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
EP1495000A4 (en) * 2002-04-08 2005-10-05 Ranbaxy Lab Ltd Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
EP1494674A4 (en) * 2002-04-08 2006-04-12 Ranbaxy Lab Ltd Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers

Also Published As

Publication number Publication date
WO2005018643A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
IL174989A0 (en) 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer
EP1945631B8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
MXPA03004794A (en) New mandelic acid derivatives and their use as throbin inhibitors.
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2002360561A1 (en) 4-substituted piperidines, and methods of use thereof
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
ATE267201T1 (en) 4-(2-PHENYLTHIAZOLE-5-YL)1,4- DIAZABICYCLO(3.2.2)NONANE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
AU2001266575A1 (en) Chemical compounds
IL176513A0 (en) Diarylmethyl piperazine derivatives, preparations thereof and used thereof
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2001238690A1 (en) 3-substituted piperidines comprising urea functionality, and methods of use thereof
MXPA03008896A (en) Indolinones, substituted in position 6, and their use as kinase inhibitors.
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
AP2005003362A0 (en) Formulation and methods for the treatment of thrombocythemia.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002210444A1 (en) Quinazolines, medicaments, which contain these compounds and which are effectiveas tyrosine kinase inhibitors, their use, and methods for the production thereo f
AU2003259391A1 (en) Metabolites of 1-{3-4`4-(2-methoxyphenyl) piperazin-1-yl!-propyl}-piperidine-2, 6-dione for use in the treatment of benign prostatic hyperplasia
WO2002056876A3 (en) Treatment for snoring
AU2002324817A1 (en) Enantiomers of 6-((4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl)4-(3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl)-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
IS7705A (en) 4- (3,5-Dysyanophenoxy) pyrazole derivatives for use as reverse transcriptors in the treatment of e.g. AIDS virus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase